High-dose extended-release calcifediol successfully treated advanced secondary hyperparathyroidism in an end-stage kidney disease patient: a case report

High-dose extended-release calcifediol successfully treated advanced secondary hyperparathyroidism in an end-stage kidney disease patient: a case report

Abstract Background Hemodialysis (HD) patients lose renal CYP27B1 (cytochrome P450 25-hydroxyvitamin D-1α-hydroxylase) as kidney function declines causing low serum total 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), and elevated intact parathyroid hormone (iPTH). Most require vitam...

Full description

Saved in:
Bibliographic Details
Main Authors: Akhtar Ashfaq, John Choe, Samir Tabash, Stephen A. Strugnell, Laura L. Johnson, Charles W. Bishop
Format: Article
Language:English
Published: BMC 2025-08-01
Series:BMC Nephrology
Subjects:
Extended-release calcifediol
Secondary hyperparathyroidism
End-stage kidney disease
Vitamin D
Case report
Online Access:https://doi.org/10.1186/s12882-025-04361-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12882-025-04361-3

Similar Items